Item 7.01 Regulation FD Disclosure

On January 9, 2023, Trevena, Inc. (the "Company") updated its website to include an updated corporate presentation deck. A copy of the updated corporate deck is attached hereto as Exhibit 99.1.

Also on January 9, 2023, the Company updated its website to include a TRV045 overview deck. A copy of the TRV045 overview deck is attached hereto as Exhibit 99.2.

The information set forth on this Item 7.01 and furnished hereto as Exhibits 99.1 and 99.2 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, and is not incorporated by reference into any of the Company's filings under the Securities Act or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.




Item 8.01 Other Events.

On January 9, 2023, the Company issued a press release announcing the enrollment of the first subject in a Phase 1 proof-of-concept study of TRV045, a novel sphingosine-1-phosphate receptor modulator selective for the S1P receptor subtype 1. The Phase 1 study will use a validated set of analgesic tests to evaluate potential central and peripheral nervous system effects and to provide insight into the potential anti-inflammatory actions of TRV045. A copy of the press release is filed as Exhibit 99.3 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits.



Exhibit
No.                                         Description
  99.1       Corporate Presentation Deck dated January 9, 2023
  99.2       TRV045 Overview Deck dated January 9, 2023
  99.3       Press Release dated January 9, 2023
104        The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

© Edgar Online, source Glimpses